WP
AVTX icon

Woodline Partners’s Avalo Therapeutics AVTX Stock Holding History

Woodline Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,041
Closed -$945K – 1036
2025
Q4 		$945K Buy
+52,041
New +$878K ﹤0.01% 844

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Woodline Partners's AVTX Position: Q1 2026 in Review

Woodline Partners sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 52,041 shares — an estimated $945K sold.

Woodline Partners first reported a position in AVTX in Q4 2025 and held it in 1 quarter. The position peaked at $945K in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Woodline Partners reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 52,041 Avalo Therapeutics shares in Q1 2026, an estimated $945K.
  • Woodline Partners first reported a position in Avalo Therapeutics in Q4 2025 and held it in 1 quarter.
  • Woodline Partners's Avalo Therapeutics position peaked at $945K in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.